VICTORIA, British Columbia--(BUSINESS WIRE)--Jul 30, 2018--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s second quarter 2018 financial results and provide a general business update.

The conference call and webcast is scheduled for August 9, 2018 at 4:30pm EDT. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN, FSGS and DES. The company is headquartered in Victoria, BC and focuses its development efforts globally. For further information, see our website at

We seek safe harbor.

View source version on

CONTACT: Aurinia Pharmaceuticals

Investor Contact:

Celia Economides

VP, Corporate & Public Affairs



Christopher Hippolyte, 212-364-0458



SOURCE: Aurinia Pharmaceuticals Inc.

Copyright Business Wire 2018.

PUB: 07/30/2018 04:20 PM/DISC: 07/30/2018 04:20 PM